Published in:
01-09-2014 | Reports of Original Investigations
Comparative efficacy of uterotonic agents: in vitro contractions in isolated myometrial strips of labouring and non-labouring women
Published in: Canadian Journal of Anesthesia/Journal canadien d'anesthésie | Issue 9/2014
Login to get accessAbstract
Purpose
To compare the in vitro contractile responses to oxytocin, ergonovine, prostaglandin F2 alpha (PGF2α), and misoprostol in isolated myometrium from non-labouring and labouring pregnant women.
Methods
Myometrial strips obtained from labouring (with or without oxytocin augmentation) and non-labouring women undergoing Cesarean deliveries were subjected to a dose-response testing with oxytocin, ergonovine, PGF2α, or misoprostol (10−10 M to 10−5 M). The amplitude and frequency of contractions, motility index (MI) (amplitude × frequency), and area under the curve during the dose-response period were recorded. The primary outcome was the motility index. Data were analyzed using linear regression models.
Results
We performed 130 experiments in myometrial strips obtained from 46 women. The overall MI (√gram·contractions·10 min−1 [√g·c·10 min−1]) was greatest for oxytocin (mean 5.10 √g·c·10 min−1; 95% confidence interval [CI] 4.70 to 5.50) than for ergonovine (mean 3.46 √g·c·10 min−1; 95% CI 3.13 to 3.80; P < 0.001), PGF2α (mean 2.64 √g·c·10 min−1; 95% CI 2.40 to 2.87; P < 0.001), and misoprostol (2.52 √g·c·10 min−1; 95% CI 2.22 to 2.82; P < 0.001). The MI for oxytocin was significantly lower in augmented labour (mean 4.11 √g·c·10 min−1; 95% CI 3.48 to 4.73) than in non-augmented labour (mean 5.19 √g·c·10 min−1; 95% CI 4.39 to 6.00; P = 0.04) or in absence of labour (mean 5.80 √g·c·10 min−1; 95% CI 5.36 to 6.24; P < 0.001). Nevertheless, in augmented labour, oxytocin still produced superior contractions compared with other uterotonic drugs. Responses to ergonovine, PGF2α, and misoprostol were unaffected by labour or prior exposure to oxytocin.
Conclusion
Oxytocin induces superior myometrial contractions compared with ergonovine, PGF2α, and misoprostol. The effect of oxytocin is reduced in myometrium of women with oxytocin-augmented labour; however, it is still superior to the other uterotonics. This trial was registered at ClinicalTrials.gov: NCT01689311.